Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Advaxis Inc
CEO
Mr. Kenneth A. Berlin J.D.
Employees
20
Industry
Biotechnology
Sector
Healthcare
Market cap
$129,181
Company details
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Revenue
Cost of goods
Revenue (Rev)
$9,000.00
Cost of goods (CoG)
-$9,000.00
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$9.78
Margin profit
0.00%
52 week low
$0.0012
52 week high
$1.31
50-day simple moving average
$0.04
200-day simple moving average
$0.06
Percent held by insiders
0.00%
Percent held by institutions
10.23%
Dividend yield
0.00%
